<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Papillary thyroid cancer: Clinical features and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Papillary thyroid cancer: Clinical features and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Papillary thyroid cancer: Clinical features and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Michael Tuttle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid follicular epithelial-derived cancers include papillary, follicular, and anaplastic cancer. Papillary and follicular cancers are considered differentiated cancers, and patients with these tumors are often treated similarly despite numerous biologic differences. The general pathogenetic, pathologic, and prognostic features of papillary thyroid cancer and its variants will be discussed here. The staging and treatment of well-differentiated thyroid cancers as well as an overview of follicular thyroid cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>In a report based upon the Surveillance, Epidemiology, and End Results (SEER) database from 1975 to 2018, the incidence of papillary cancer increased from 4.8 to 14.9 per 100,000, stabilized, and then appeared to decline to approximately 13.5 per 100,000 by 2018  (<a class="graphic graphic_figure graphicRef107600" href="/z/d/graphic/107600.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>]. The death rates (0.5 per 100,000 male and female per year) did not change significantly. The 5-year relative survival remains quite high at 98.3 percent (2011 to 2017 data).</p><p>The precise reasons for the increase, apparent plateau, and subsequent decrease in incidence rate in papillary thyroid cancer are unknown. The initial increase in thyroid cancer in the United States incidence was seen in both sexes and all ethnic backgrounds  (<a class="graphic graphic_figure graphicRef107601" href="/z/d/graphic/107601.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef107603" href="/z/d/graphic/107603.html" rel="external">figure 3</a>) [<a href="#rid3">3,4</a>]. The usual female-to-male ratio of papillary thyroid cancer is approximately 2.5:1, with most of the female preponderance occurring during the fourth and fifth decades of life. </p><p>The increased incidence was thought to partially reflect earlier detection of subclinical disease (ie, small papillary cancers) secondary to more widespread use of neck ultrasonography and fine-needle aspiration (FNA) of very small thyroid nodules [<a href="#rid5">5-7</a>]. However, an analysis of the National Cancer Institute's SEER database found an increase in the rates of differentiated thyroid cancer of all sizes, including tumors greater than 4 cm [<a href="#rid8">8</a>]. Subsequently, there has been a move in the medical community away from the previous widespread practice of immediate biopsy of very small asymptomatic suspicious nodules incidentally detected on imaging. More selective use of FNA in small thyroid nodules along with more judicious use of thyroid ultrasonography, in general, could lead to a decrease in incident rates. However, another primary cause of thyroid cancer (as yet unidentified) has not been excluded.</p><p class="headingAnchor" id="H3"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H4"><span class="h2">Radiation exposure</span><span class="headingEndMark"> — </span>Radiation exposure of the thyroid during childhood is the most clearly defined environmental factor associated with benign and malignant thyroid tumors [<a href="#rid9">9</a>]. Potential sources of radiation exposure include therapeutic uses of radiation (eg, treatment of childhood malignancies), environmental exposure secondary to fallout from atomic weapons (eg, Nagasaki/Hiroshima, Japan), or nuclear power plant accidents (eg, Chernobyl). In the past, ionizing radiation was used to treat a wide variety of benign conditions of the head and neck, although this practice essentially ceased in the late 1950s to early 1960s due to increased appreciation of the carcinogenic effects of radiation on the thyroid. (See  <a class="medical medical_review" href="/z/d/html/7059.html" rel="external">"Radiation-induced thyroid disease"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Family history</span><span class="headingEndMark"> — </span>A history of thyroid cancer in a first-degree relative or a family history of a thyroid cancer syndrome (eg, familial polyposis, Carney complex, multiple endocrine neoplasia type 2 [MEN2], Werner syndrome, or Cowden syndrome) increases the risk that a nodule may be malignant. In one study, there was a 10-fold increased risk of thyroid cancer in relatives of thyroid cancer patients [<a href="#rid10">10</a>]. In a second report, the standardized incidence ratio for papillary cancer was 3.2 with an involved parent, 6.2 with an involved sibling, and 11.2 for a female with an involved sister [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Other</span><span class="headingEndMark"> — </span>A number of other possible (but not proven) risk factors have been reported. Their relative importance appears to be small but not completely defined. Potential risk factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Occupational and environmental exposures [<a href="#rid12">12,13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis C-related chronic hepatitis (odds ratio [OR] 12.2 in one report) [<a href="#rid14">14</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Increased parity and late age at first pregnancy [<a href="#rid15">15</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity or overweight [<a href="#rid16">16</a>]</p><p></p><p class="headingAnchor" id="H8"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Mutations or rearrangements in the genes encoding for the proteins in the mitogen-activated protein kinase (MAPK) pathway are critical to the development and progression of differentiated thyroid cancer  (<a class="graphic graphic_figure graphicRef71801" href="/z/d/graphic/71801.html" rel="external">figure 4</a>) [<a href="#rid17">17,18</a>]. The importance of this pathway is demonstrated by nonoverlapping, mutually exclusive mutations of genes encoding effectors that signal through the MAPK pathway. Activating mutations in <em>BRAF </em>V600E are most common (60 percent) followed by <em>RAS</em> mutations (15 percent), and chromosomal rearrangements that activate kinase domains of <em>BRAF</em> or receptor kinases such as RET, NTRK, or ALK (12 percent). The remaining 13 percent usually have copy number alterations but without an identifiable driver mutation [<a href="#rid19">19</a>].</p><p>The molecular profile of Hürthle cell thyroid carcinomas (oncocytic thyroid cancers) has been shown to be quite different from papillary or follicular thyroid cancers. Rather than having the classic activation of the MAPK pathway seen in papillary/follicular thyroid cancers, Hürthle cell carcinomas demonstrate widespread mitochondrial losses, mitochondrial DNA mutations, and a series of novel putative driver mutations [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer", section on 'Papillary thyroid cancer'</a>.)</p><p class="headingAnchor" id="H13329960"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H9"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Thyroid cancer typically presents as a thyroid nodule. Thyroid nodules come to clinical attention when noted by the patient; during routine physical examination; or when incidentally noted during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scanning. Nonpalpable nodules (incidentalomas) have the same risk of malignancy as palpable nodules of the same size. </p><p>A history of rapid nodular growth, fixation of the nodule to surrounding tissues, new-onset hoarseness or vocal cord paralysis, or the presence of ipsilateral cervical lymphadenopathy all raise the suspicion that a nodule may be malignant. Regardless of how thyroid nodules are discovered, the diagnosis of thyroid cancer is usually made by fine-needle aspiration (FNA) biopsy  (<a class="graphic graphic_picture graphicRef71385" href="/z/d/graphic/71385.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'History and physical examination'</a> and  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Histology</span></p><p class="headingAnchor" id="H3444325047"><span class="h3">Classic form</span><span class="headingEndMark"> — </span>Papillary cancers are typically unencapsulated and may be partially cystic. Microscopically, most are characterized by the presence of papillae consisting of one or two layers of tumor cells surrounding a well-defined fibrovascular core; follicles and colloid are typically absent  (<a class="graphic graphic_picture graphicRef81310" href="/z/d/graphic/81310.html" rel="external">picture 2</a>).</p><p>The morphologic diagnosis is based upon an aggregate of typical cytologic features  (<a class="graphic graphic_picture graphicRef71385" href="/z/d/graphic/71385.html" rel="external">picture 1</a>), none by itself pathognomonic of papillary cancer. The nuclei are large, oval, and appear crowded and overlapping on microscopic sections. They may contain hypodense powdery chromatin, cytoplasmic pseudoinclusions due to a redundant nuclear membrane, or nuclear grooves.</p><p>Approximately one-half of papillary cancers contain calcified psammoma bodies, the scarred remnants of tumor papillae that presumably infarcted  (<a class="graphic graphic_picture graphicRef72821" href="/z/d/graphic/72821.html" rel="external">picture 3</a>). Inflammatory cells may surround or infiltrate areas of malignant growth, although this does not usually indicate the presence of chronic autoimmune thyroiditis (Hashimoto's disease).</p><p>Papillary thyroid cancer is often multifocal. In some cases, this represents intraglandular metastases from the primary tumor [<a href="#rid21">21</a>]. However, in one study of 10 women with multifocal papillary cancer, individual tumor foci were shown to have independent clonal origins in 5 of the 10 women [<a href="#rid22">22</a>]. In a second study, discordant patterns of <em>BRAF</em> mutations were found in 40 percent of the multifocal papillary cancers [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H145637637"><span class="h3">Variant forms</span><span class="headingEndMark"> — </span>Variant forms of papillary cancer include the follicular variant; tall cell variant (a more aggressive tumor accounting for approximately 1 percent of papillary cancers); and insular, hobnail, and diffuse sclerosing variants.</p><p class="headingAnchor" id="H2151779276"><span class="h4">Follicular variants</span><span class="headingEndMark"> — </span>Follicular variant papillary thyroid cancer demonstrates a follicular growth pattern but cytologically, the tumors display the typical features of common-type papillary cancers, including large, overlapping nuclei with hypodense chromatin, nuclear pseudoinclusions, and nuclear grooves; most also contain psammoma bodies  (<a class="graphic graphic_picture graphicRef72821" href="/z/d/graphic/72821.html" rel="external">picture 3</a>) [<a href="#rid24">24</a>].</p><p>Of the several histologic subtypes of papillary carcinoma, the follicular variants are probably the most common. The incidence of follicular variant papillary cancer has been increasing, while that of the classical form has been decreasing. In a single-center study, nearly 40 percent of the papillary cancers were follicular variants [<a href="#rid25">25</a>], and in a multicenter study, 23 percent of papillary cancers were the noninvasive, well-circumscribed subtype (noninvasive follicular thyroid neoplasm with papillary-like nuclear features, NIFTP) [<a href="#rid26">26</a>].</p><p>According to the 2017 World Health Organization classification of endocrine tumors, follicular variants of papillary thyroid cancer are subtyped as being either (1) infiltrative or (2) encapsulated with invasion [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infiltrative</strong> – The infiltrative subtype demonstrates invasive tongues of tumor infiltrating into non-neoplastic thyroid parenchyma and lacks a well-defined tumor capsule [<a href="#rid28">28</a>]. The infiltrative subtype has a biological behavior and molecular profile that is more similar to classic papillary thyroid cancer than follicular cancers [<a href="#rid28">28,29</a>]. For example, the infiltrative subtype is more likely to have lymph node metastases and <em>BRAF</em> V600E mutations, while being less likely than follicular thyroid cancers to have distant metastases or <em>RAS </em>mutations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Encapsulated with invasion</strong> – The encapsulated with invasion subtype demonstrates both a well-defined tumor capsule and either invasion of the tumor capsule or invasion into vessels within or beyond the tumor capsule. The encapsulated variants, particularly those with vascular invasion, have a tumor biology (often <em>RAS </em>mutation) and biological behavior (more likely to have distant metastases, less likely to have lymph node metastases) that is more similar to follicular thyroid cancer than to classical papillary thyroid cancer. It is the presence of either vascular or tumor capsular invasion<strong> </strong>that differentiates an encapsulated follicular variant of papillary thyroid cancer (capsular and/or vascular invasion present) from noninvasive encapsulated follicular variant of papillary thyroid cancer (NIFTP; no capsular or vascular invasion present).</p><p></p><p>In the past, encapsulated follicular variant of papillary thyroid cancer without evidence for either vascular or tumor capsule invasion were considered noninvasive variants of papillary thyroid cancer [<a href="#rid26">26,30,31</a>]. However, noninvasive encapsulated follicular variants of papillary thyroid cancer have a very low malignant potential and are uniformly cured with lobectomy [<a href="#rid32">32,33</a>]. Because of the very low malignant potential, this type was renamed noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), emphasizing that this tumor can be managed as a neoplasm rather than a malignancy [<a href="#rid32">32,33</a>]. Both the American Thyroid Association [<a href="#rid34">34</a>] and the World Health Organization have endorsed this change in nomenclature [<a href="#rid27">27</a>].</p><p>While thyroid surgery is required to distinguish NIFTP from the encapsulated with invasive subtype, therapy beyond thyroid lobectomy is usually not required (ie, thyroid-stimulating hormone [TSH] suppression and radioactive iodine ablation is not required) [<a href="#rid32">32,34,35</a>]. Proper use of the NIFTP nomenclature requires adherence to strict histopathological criteria, which means that tumors previously classified as noninvasive encapsulated follicular variant of papillary thyroid cancer cannot be assumed to be NIFTP tumors. Because the entire tumor capsule may not have been sampled or preserved at the time of initial diagnosis, it is often not possible to determine if an archived tumor sample meets all the diagnostic criteria to be reclassified as an NIFTP tumor [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults", section on 'Repeat FNA indeterminate'</a>.)</p><p class="headingAnchor" id="H1804728617"><span class="h4">Tall cell variant</span><span class="headingEndMark"> — </span>The tall cell variant form of papillary cancer has the potential to be a more aggressive tumor than classical papillary cancer [<a href="#rid36">36,37</a>]. These tumors account for approximately 1 percent of papillary cancers and are typically associated with a V600E mutation in the <em>BRAF</em> gene (see <a class="local">'Molecular characteristics'</a> below). They are characterized by tumor cells with eosinophilic cytoplasm that are twice as tall as they are wide. The primary tumors tend to be large, they are often invasive, and many patients have both local and distant metastases at the time of diagnosis [<a href="#rid36">36</a>]. Most patients have evidence of disease after initial therapy, and the five-year mortality rate is higher than in patients with classical papillary cancers.</p><p class="headingAnchor" id="H4149522028"><span class="h4">Other variants</span><span class="headingEndMark"> — </span>Several other variant types of papillary cancer have been described, also based upon histologic differences from classical papillary cancers but considered to be papillary cancers because of the characteristics of the tumor cell nuclei:</p><p class="bulletIndent1"><span class="glyph">●</span>The insular variant of papillary cancer is characterized histologically by solid nests of tumor, often separated by fibrous bands, but the tumor cell nuclei have the same characteristics as do the nuclei of classical papillary cancers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The columnar variant, which consists of elongated cells with palisading nuclei.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Hürthle or <strong>oxyphilic</strong> variant, which has cellular features of Hürthle cell carcinomas but cells that are arranged in papillary formations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The solid or <strong>trabecular</strong> variant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clear cell variant, which must be distinguished from clear cell carcinomas of other organs such as the kidney or colon that have metastasized to the thyroid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diffuse sclerosing variant, characterized by diffuse involvement of the thyroid, stromal fibrosis, and prominent lymphocytic infiltration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cribriform morular variant, which has a prominent cribriform pattern with solid and spindle cell areas as well as squamous morules. This variant is often associated with familial adenomatous polyposis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hobnail variant frequently, which harbors <em>BRAF</em> V600E mutations and appears to be associated with a high risk of distant metastases and an increased disease-specific mortality [<a href="#rid38">38,39</a>].</p><p></p><p>These variants are all rare, and therefore, little information about their characteristics is available. In general, however, they are thought to be more aggressive than classical papillary cancers. As a result, patients with these tumors are usually managed more aggressively than are those with classical papillary cancer of the same stage  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Subsequent management based on risk classification'</a> and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a> and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment"</a>.)</p><p class="headingAnchor" id="H13330006"><span class="h2">Lymph node involvement</span><span class="headingEndMark"> — </span>The incidence of nodal metastases in adults depends upon the extent of surgery. Among patients who undergo a modified radical neck dissection, up to 80 percent have lymph node metastases (half of which are microscopic), and even among patients with papillary microcarcinomas who have prophylactic central node dissection, microscopic metastases have been reported in 37 to 64 percent [<a href="#rid40">40</a>]. At diagnosis, clinically detectable regional lymph node metastases are more common in children (approximately 50 percent) than adults.</p><p>Invasion of either the thyroid capsule or a lymph node capsule into surrounding soft tissue has been reported in 5 to 35 percent of surgical specimens, whereas vascular invasion is seen in only approximately 5 to 10 percent.</p><p class="headingAnchor" id="H13329994"><span class="h2">Metastases</span><span class="headingEndMark"> — </span>From 2 to 10 percent of patients have metastases beyond the neck at the time of diagnosis [<a href="#rid1">1</a>]. Among such patients, two-thirds have pulmonary and one-fourth have skeletal metastases. Rarer sites of metastasis are the brain, kidneys, liver, and adrenals.</p><p class="headingAnchor" id="H13330000"><span class="h2">Growth pattern</span><span class="headingEndMark"> — </span>The growth pattern and biologic behavior of papillary cancer are variable.</p><p class="bulletIndent1"><span class="glyph">●</span>At one end of the spectrum is the common microcarcinoma (formerly called occult papillary cancer), defined as a tumor &lt;1 cm in diameter. These microcarcinomas are found in 15 to 30 percent of thyroid glands at autopsy. This high frequency, coupled with the rarity of clinically detected papillary cancer, suggests that the presence of a single focus of microcarcinoma in a thyroidectomy specimen is likely to be an incidental finding of no clinical importance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the other end of the spectrum is a large, locally invasive cancer with distant metastases noted at the time of diagnosis. These tumors are also far more likely than microcarcinoma to metastasize through intrathyroidal lymphatic channels and form multifocal tumors or involve regional lymph nodes.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">PROGNOSTIC FEATURES</span><span class="headingEndMark"> — </span>Most patients with papillary cancer do not die of their disease. As an example, in one series of patients with a median follow-up of 16 years, the cancer-related mortality in patients without metastases at presentation was only 6 percent [<a href="#rid41">41</a>].</p><p>While there are a wide variety of staging systems available to predict disease-specific survival and risk of structural disease recurrence, there are a small set of key factors that identify the relatively small group of patients that are likely to do poorly [<a href="#rid42">42</a>]. Patients at highest risk of dying from thyroid cancer are older patients (&gt;55 years of age at diagnosis) presenting with distant metastases or gross invasion of the tumor into the airway, nerves, or major vessels of the neck  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>) [<a href="#rid43">43</a>]. Similarly, patients at highest risk of structural recurrence demonstrate gross invasion into major neck structures, distant metastases, palpable metastatic lymph node metastases, extensive microscopic vascular invasion, or inappropriately elevated serum thyroglobulin after initial therapy  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>) [<a href="#rid42">42</a>].</p><p>The extent of initial surgery and the use of radioiodine therapy in advanced papillary cancers are associated with improved outcomes. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Choice of procedure'</a> and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Age</span><span class="headingEndMark"> — </span>Thyroid cancer mortality increases progressively with advancing age, without a specific age cutoff that stratifies mortality risk [<a href="#rid44">44</a>]. This was illustrated in an analysis of 53,581 patients in the Surveillance, Epidemiology, and End Results (SEER) database, in which the five-year survival rate decreased with increasing age at diagnosis (stratified in five-year categories from 20 to 84 years) [<a href="#rid45">45</a>]. There was a continuum of disease-specific mortality with increasing age. Survival remained above 90 percent for patients &lt;65 years at diagnosis.</p><p class="headingAnchor" id="H13"><span class="h2">Tumor size</span><span class="headingEndMark"> — </span>The prognosis is poorer in patients who have large tumors [<a href="#rid46">46,47</a>]. In one series, as an example, 20-year cancer-related mortality rates were 6, 16, and 50 percent for patients whose primary tumor diameters were 2 to 3.9 cm, 4 to 6.9 cm, or 7 cm or larger, respectively [<a href="#rid46">46</a>].</p><p>While small tumors usually have an excellent prognosis, clinically evident recurrences are not infrequently detected. A survey of 299 patients with thyroid cancers less than 1.5 cm found no deaths over a mean follow-up of 45 months, but 14.4 percent had evidence of persistent/recurrent disease. Persistent or recurrent disease was associated with nonincidental cancer, lymph node metastases at presentation, or bilateral tumor but not size [<a href="#rid48">48</a>]. This study only compared tumors greater or less than 1 cm. In another study of 3965 patients with thyroid cancer (65 percent with tumors ≤2 cm), 10-year recurrence rates to the thyroid, lymph nodes, and distant organs for tumors ≤2 cm were 0.3, 1.9, and 0.4 percent, respectively [<a href="#rid49">49</a>]. Recurrence rates increased with tumor size (for tumors &gt;4 cm 1.9, 8.1, and 3.4 percent, respectively). Mortality was low in both groups (0.04 and 0.4 percent, respectively).</p><p class="headingAnchor" id="H14"><span class="h2">Soft-tissue invasion</span><span class="headingEndMark"> — </span>When present, clinically apparent, gross soft-tissue invasion increases the risk of death fivefold. It can also cause substantial morbidity if there is involvement of the trachea, esophagus, recurrent laryngeal nerves, or the spinal cord. It is important to note that it is gross soft-tissue invasion (usually described as extrathyroidal extension) identified on clinical examination, intraoperatively, or on imaging that conveys an increased risk of mortality. Extrathyroidal extension that is only identified on histopathologic examination is not a major factor for mortality, as reflected in the changes in the eighth edition American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system where minor extrathyroidal extension no longer upstages a patient to stage III  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>). (See <a class="local">'Staging'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Distant metastases</span><span class="headingEndMark"> — </span>The rate of survival in patients with distant metastases is variable, depending upon the site of metastases. Among patients with small pulmonary metastases but no other metastases outside of the neck, the 10-year survival rate is 30 to 50 percent; even higher survival rates have been reported in patients whose pulmonary metastases were detected only by radioiodine imaging [<a href="#rid50">50</a>]. Conversely, the median survival of patients with brain metastases is only approximately one year [<a href="#rid51">51</a>].</p><p>In multivariate analysis, fluorodeoxyglucose (FDG) positivity was the most powerful predictor of death in a large cohort of patients with metastatic disease. Patients with large-volume, intense FDG uptake had a three-year, disease-specific survival less than 50 percent from the time of the positron emission tomography (PET) scan [<a href="#rid52">52</a>]. This may be due in part to lower radioiodine avidity in papillary cancers demonstrating a high FDG uptake.</p><p class="headingAnchor" id="H612252231"><span class="h2">Histologic subtype</span><span class="headingEndMark"> — </span>Several studies have demonstrated a poorer prognosis for specific subtypes of papillary thyroid cancers, including tall cell, insular, and hobnail variants [<a href="#rid38">38,53</a>]. (See <a class="local">'Variant forms'</a> above.)</p><p>In one study of 62 patients with the tall cell variant of papillary cancer without extrathyroidal extension at presentation, prognosis was still worse compared with classic papillary cancer; 6.4 percent developed distant metastases versus none of the patients in a comparison group with classic papillary cancer [<a href="#rid53">53</a>]. However, among patients without initial lymph node metastases or extrathyroidal invasion, no one developed metastatic disease.</p><p>Patients with aggressive histologic subtypes are usually treated more aggressively than are those with common-type papillary cancer of the same stage  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Risk classification'</a>.)</p><p class="headingAnchor" id="H4161631315"><span class="h2">Molecular characteristics</span><span class="headingEndMark"> — </span>In addition to the traditional histopathologic risk factors, specific molecular profiles (eg, <em>BRAF</em>, telomerase reverse transcriptase [<em>TERT]</em>) may be used to predict risk of extrathyroidal extension, lymph node metastases, and even distant metastases [<a href="#rid54">54-56</a>]. While these observations need further validation, it is likely that the specific molecular profile of the primary tumor may have significant prognostic value that could be incorporated into stratification systems.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of low-risk patients with intrathyroidal papillary thyroid cancer (&lt;4 cm, N0, M0; 33 percent with <em>BRAF</em> mutation), the overall risk of having structural disease recurrence over five years of follow-up was 3 percent [<a href="#rid57">57</a>]. However, <em>BRAF</em> V600E mutated tumors had a recurrence rate of 8 percent (8 of 106) compared with only 1 percent (2 of 213) in <em>BRAF</em>-negative tumors. Furthermore, in multivariate analysis, the only clinicopathologically significant predictor of persistent disease after five years of follow-up was the presence of mutated <em>BRAF</em> V600E.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>TERT</em> mutations have been described in 7 to 22 percent of papillary and 14 to 17 percent of follicular thyroid cancer but with a significantly higher prevalence in aggressive thyroid cancer [<a href="#rid58">58-61</a>]. In the largest reported series (332 papillary and 70 follicular thyroid cancer followed on average for eight years), <em>TERT</em> mutation was an independent predictor of persistent disease (odds ratio [OR] 4.68, 95% CI 1.54-14.27) and mortality (hazard ratio [HR] 10.35, 95% CI 2.01-53.24) for well-differentiated thyroid cancer [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of vascular endothelial growth factor (<em>VEGF</em>, a potent stimulator of endothelial cell proliferation) in thyroid cancer specimens may help predict the presence of metastases. As an example, in a retrospective study of 19 patients with papillary cancer, a high level of immunostaining for VEGF correlated with a high risk of metastatic disease [<a href="#rid62">62</a>]. In a second report, elevated preoperative serum VEGF-C concentrations were an independent risk factor for nodal metastases and advanced tumor stages [<a href="#rid63">63</a>].</p><p></p><p>A broader genetic analysis may provide more accurate tumor prognostication. Specifically, a growing body of data suggest that a more aggressive clinical course can be expected in tumors that carry: (1) <em>BRAF</em> V600E in combination with other driver oncogenic mutations such as <em>PIK3CA</em>, <em>TP53</em>, <em>AKT1</em>, or <em>RET</em>/PTC mutation [<a href="#rid64">64-66</a>]; (2) <em>TERT</em> mutations, isolated or in combination with <em>BRAF</em> [<a href="#rid58">58,67</a>]; or (3) <em>TP53</em> mutations [<a href="#rid68">68</a>].</p><p>These results, although pending confirmation in other studies, suggest that specific molecular profiles may eventually prove to be a useful adjunct to risk stratification. (See  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer"</a> and  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'Other prognostic factors'</a>.)</p><p>Whether the presence of <em>BRAF</em> independently predicts mortality is uncertain. Although in a retrospective analysis, the presence of a <em>BRAF</em> V600E mutation was associated with thyroid cancer mortality (overall mortality 5.3 versus 1.1 percent in <em>BRAF</em> V600E-positive versus mutation-negative patients), the association was no longer significant after adjusting for clinical and histopathologic features, including lymph node metastases, extrathyroidal invasion, and distant metastasis [<a href="#rid69">69,70</a>]. However, <em>BRAF</em> V600E mutation does appear to have a significant interaction with important clinicopathologic risk factors as the risk of mortality was higher in <em>BRAF</em> mutated versus <em>BRAF</em> wild-type tumors in the setting of lymph node metastases, distant metastases, and age greater than 45 years at diagnosis [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H3715062197"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Other factors associated with a minor increase in the risk of either recurrence or death are [<a href="#rid71">71,72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multicentricity of intrathyroidal tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral or mediastinal lymph node involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Greater than 10 nodal metastases</p><p class="bulletIndent1"><span class="glyph">●</span>Nodal metastases with extranodal extension</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Delay in primary surgical therapy of more than one year after detection of a thyroid nodule</p><p></p><p class="headingAnchor" id="H17"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Postoperative staging, based upon the clinicopathologic features of each case, is important for providing prognostic information. We use both the tumor, node, metastasis (TNM) classification scheme for prediction of disease-specific mortality  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 2</a>) and the American Thyroid Association (ATA) risk of recurrence staging system for initial assessment of risk of recurrence  (<a class="graphic graphic_table graphicRef52272" href="/z/d/graphic/52272.html" rel="external">table 1</a>). While initial risk stratification can be used to guide initial therapeutic and diagnostic follow-up strategy decisions, it is important to recognize that initial risk estimates may need to change as new data are accumulated during follow-up for each individual patient. Staging is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a>.)</p><p class="headingAnchor" id="H21824182"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82979.html" rel="external">"Patient education: Thyroid cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – The incidence of papillary thyroid cancer in the United States increased dramatically between 1975 and 2012, plateaued, and then subsequently declined  (<a class="graphic graphic_figure graphicRef107600" href="/z/d/graphic/107600.html" rel="external">figure 1</a>). The precise reasons for the increase, apparent plateau, and subsequent decrease in incidence rate in papillary thyroid cancer are unknown. The recent decrease may be related, in part, to changing practice with more judicious use of thyroid ultrasonography and more selective use of fine-needle aspiration (FNA) of small thyroid nodules. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for papillary thyroid cancer include a history of radiation exposure during childhood, a history of thyroid cancer in a first-degree relative, or a family history of a thyroid cancer syndrome. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Mutations or rearrangements in the genes encoding for the proteins in the mitogen-activated protein kinase (MAPK) pathway are critical to the development and progression of differentiated thyroid cancer  (<a class="graphic graphic_figure graphicRef71801" href="/z/d/graphic/71801.html" rel="external">figure 4</a>). Activating mutations in <em>BRAF </em>V600E are most common (60 percent) followed by <em>RAS</em> mutations (15 percent), and chromosomal rearrangements that activate kinase domains of <em>BRAF</em> or receptor kinases such as RET, NTRK, or ALK (12 percent). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Thyroid cancer typically presents as a thyroid nodule. Thyroid nodules come to clinical attention when noted by the patient; during routine physical examination; or when incidentally noted during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scanning. Nonpalpable nodules (incidentalomas) have the same risk of malignancy as palpable nodules of the same size. (See <a class="local">'Clinical presentation'</a> above and  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic subtypes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classic form</strong> – Papillary cancers are typically unencapsulated and may be partially cystic. Microscopically, most are characterized by the presence of papillae consisting of one or two layers of tumor cells surrounding a well-defined fibrovascular core; follicles and colloid are typically absent  (<a class="graphic graphic_picture graphicRef81310" href="/z/d/graphic/81310.html" rel="external">picture 2</a>). (See <a class="local">'Classic form'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Variant forms</strong> – Variant forms of papillary cancer include follicular, tall cell, insular, and hobnail variants. Of the several histologic subtypes of papillary carcinoma, the follicular variants are probably the most common.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Follicular variants</strong> – According to the 2017 World Health Organization classification of endocrine tumors, follicular variants of papillary thyroid cancer are subtyped as being either (1) infiltrative or (2) encapsulated with invasion.</p><p></p><p class="bulletIndent3">Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP, formerly called noninvasive follicular variant of papillary thyroid cancer, but subsequently reclassified as a nonmalignant variant because it does not have either vascular or tumor capsule invasion) has an excellent prognosis. While thyroid surgery is required to distinguish NIFTP from the encapsulated with invasion subtype, therapy beyond thyroid lobectomy is usually not required. (See <a class="local">'Follicular variants'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tall cell and other variants</strong> – Other variant forms of papillary cancer are thought to be more aggressive than common-type papillary cancers. As a result, patients with these tumors are usually managed more aggressively than are those with common-type papillary cancer of the same stage. (See <a class="local">'Tall cell variant'</a> above and <a class="local">'Other variants'</a> above and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Risk classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic features</strong> – Clinical and pathologic features associated with a somewhat higher risk for tumor recurrence and cancer-related mortality include older age at diagnosis, size of primary tumor, and the presence of soft-tissue invasion or distant metastases. (See <a class="local">'Prognostic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of differentiated thyroid cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">http://seer.cancer.gov/statfacts/html/thyro.html (Accessed on April 14, 2022).</li><li><a class="nounderline abstract_t">Powers AE, Marcadis AR, Lee M, et al. Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016. JAMA 2019; 322:2440.</a></li><li class="breakAll">Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2004/ (Accessed on November 29, 2007).</li><li><a class="nounderline abstract_t">Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.</a></li><li><a class="nounderline abstract_t">Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140:317.</a></li><li><a class="nounderline abstract_t">Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med 2014; 371:1765.</a></li><li><a class="nounderline abstract_t">Vaccarella S, Franceschi S, Bray F, et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med 2016; 375:614.</a></li><li><a class="nounderline abstract_t">Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017; 317:1338.</a></li><li><a class="nounderline abstract_t">Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 2005; 1:82.</a></li><li><a class="nounderline abstract_t">Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307.</a></li><li><a class="nounderline abstract_t">Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005; 90:5747.</a></li><li><a class="nounderline abstract_t">Nagataki S, Nyström E. Epidemiology and primary prevention of thyroid cancer. Thyroid 2002; 12:889.</a></li><li><a class="nounderline abstract_t">Boice JD Jr, Lubin JH. Occupational and environmental radiation and cancer. Cancer Causes Control 1997; 8:309.</a></li><li><a class="nounderline abstract_t">Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17:447.</a></li><li><a class="nounderline abstract_t">Rossing MA, Voigt LF, Wicklund KG, Daling JR. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 2000; 151:765.</a></li><li><a class="nounderline abstract_t">Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995-2015). J Natl Cancer Inst 2020; 112:810.</a></li><li><a class="nounderline abstract_t">Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004; 183:249.</a></li><li><a class="nounderline abstract_t">Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6:292.</a></li><li><a class="nounderline abstract_t">Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 2016; 375:1054.</a></li><li><a class="nounderline abstract_t">Ganly I, McFadden DG. Short Review: Genomic Alterations in Hürthle Cell Carcinoma. Thyroid 2019; 29:471.</a></li><li><a class="nounderline abstract_t">McCarthy RP, Wang M, Jones TD, et al. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res 2006; 12:2414.</a></li><li><a class="nounderline abstract_t">Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352:2406.</a></li><li><a class="nounderline abstract_t">Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92:3511.</a></li><li><a class="nounderline abstract_t">Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 1994; 73:424.</a></li><li><a class="nounderline abstract_t">Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014; 99:E276.</a></li><li><a class="nounderline abstract_t">Faquin WC, Wong LQ, Afrogheh AH, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 2016; 124:181.</a></li><li class="breakAll">Rosai J, Albores Saavedra J, Asioli S, et al. Papillary thyroid cancer. In: WHO Classification of Tumours of Endocrine Organs, 4th, Lloyd RV, Osamura RY, Klöppel G, Rosai J (Eds), International Agency for Research on Cancer, Lyon 2017. p.65.</li><li><a class="nounderline abstract_t">Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006; 107:1255.</a></li><li><a class="nounderline abstract_t">Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23:1191.</a></li><li><a class="nounderline abstract_t">Daniels GH. What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 2011; 17:768.</a></li><li><a class="nounderline abstract_t">Ganly I, Wang L, Tuttle RM, et al. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol 2015; 46:657.</a></li><li><a class="nounderline abstract_t">Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol 2016; 2:1023.</a></li><li><a class="nounderline abstract_t">Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features. JAMA Oncol 2018; 4:1125.</a></li><li><a class="nounderline abstract_t">Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid 2017; 27:481.</a></li><li><a class="nounderline abstract_t">Hodak S, Tuttle RM, Maytal G, et al. Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer-Primum Non Nocere and NIFTP. Thyroid 2016; 26:869.</a></li><li><a class="nounderline abstract_t">Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988; 12:22.</a></li><li><a class="nounderline abstract_t">Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18:1179.</a></li><li><a class="nounderline abstract_t">Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010; 34:44.</a></li><li><a class="nounderline abstract_t">Motosugi U, Murata S, Nagata K, et al. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid 2009; 19:535.</a></li><li><a class="nounderline abstract_t">Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.</a></li><li><a class="nounderline abstract_t">Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43:401.</a></li><li><a class="nounderline abstract_t">Tuttle RM Md, Haugen BR Md, Perrier N. The Updated AJCC/TNM Staging System for Differentiated and Anaplastic Thyroid Cancer (8th edition): What changed and why? Thyroid 2017.</a></li><li><a class="nounderline abstract_t">Ganly I, Nixon IJ, Wang LY, et al. Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It? Thyroid 2015; 25:1106.</a></li><li><a class="nounderline abstract_t">Bischoff LA, Curry J, Ahmed I, et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract 2013; 19:995.</a></li><li><a class="nounderline abstract_t">Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050.</a></li><li><a class="nounderline abstract_t">Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269.</a></li><li><a class="nounderline abstract_t">Pellegriti G, Scollo C, Lumera G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004; 89:3713.</a></li><li><a class="nounderline abstract_t">Ito Y, Kudo T, Kihara M, et al. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J 2012; 59:119.</a></li><li><a class="nounderline abstract_t">Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626.</a></li><li><a class="nounderline abstract_t">Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637.</a></li><li><a class="nounderline abstract_t">Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498.</a></li><li><a class="nounderline abstract_t">Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007; 17:655.</a></li><li><a class="nounderline abstract_t">Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373.</a></li><li><a class="nounderline abstract_t">Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38.</a></li><li><a class="nounderline abstract_t">Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118:1764.</a></li><li><a class="nounderline abstract_t">Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012; 97:4390.</a></li><li><a class="nounderline abstract_t">Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014; 99:E754.</a></li><li><a class="nounderline abstract_t">Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013; 20:603.</a></li><li><a class="nounderline abstract_t">Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013; 98:E1562.</a></li><li><a class="nounderline abstract_t">Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014; 99:E1130.</a></li><li><a class="nounderline abstract_t">Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:656.</a></li><li><a class="nounderline abstract_t">Yu XM, Lo CY, Lam AK, et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008; 247:483.</a></li><li><a class="nounderline abstract_t">Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399.</a></li><li><a class="nounderline abstract_t">Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009; 15:485.</a></li><li><a class="nounderline abstract_t">Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69:4885.</a></li><li><a class="nounderline abstract_t">Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014; 32:2718.</a></li><li><a class="nounderline abstract_t">Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013; 98:E1852.</a></li><li><a class="nounderline abstract_t">Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309:1493.</a></li><li><a class="nounderline abstract_t">Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 2013; 309:1529.</a></li><li><a class="nounderline abstract_t">Lin JD, Chao TC, Hsueh C, Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol 2009; 16:2609.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005; 90:5723.</a></li></ol></div><div id="topicVersionRevision">Topic 7860 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://seer.cancer.gov/statfacts/html/thyro.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : http://seer.cancer.gov/statfacts/html/thyro.html (Accessed on April 14, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860035" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860035" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297039" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24557566" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Current thyroid cancer trends in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372084" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532827" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362912" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929376" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term risks for thyroid cancer and other neoplasms after exposure to radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701697" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030170" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Familial risks for nonmedullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487771" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology and primary prevention of thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498895" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Occupational and environmental radiation and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17542674" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10965973" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reproductive factors and risk of papillary thyroid cancer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31638139" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995-2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531713" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16557281" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathogenetic mechanisms in thyroid follicular-cell neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biologic and Clinical Perspectives on Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848171" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Short Review: Genomic Alterations in Hürthle Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638846" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15944425" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535994" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293410" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248188" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457584" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457584" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900519" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526288" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940284" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25721865" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078145" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29902314" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28114862" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27184034" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer-Primum Non Nocere and NIFTP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337337" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prognostic implications of the tall cell variant of papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18925842" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Papillary thyroid carcinoma tall cell variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19956062" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19348583" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083442" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977430" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891169" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Update on differentiated thyroid cancer staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28463585" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Updated AJCC/TNM Staging System for Differentiated and Anaplastic Thyroid Cancer (8th edition): What changed and why?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26148759" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013977" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256208" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15856429" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292295" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068114" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410272" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360519" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognosis and treatment of brain metastases in thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303836" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696836" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174717" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520704" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21882184" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23066120" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476079" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23766237" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Highly prevalent TERT promoter mutations in aggressive thyroid cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23833040" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24617711" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158026" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376194" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602780" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147753" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487299" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25024077" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979959" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571588" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571594" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Molecular testing in thyroid cancer: BRAF mutation status and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19533244" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High recurrent rate of multicentric papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030160" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
